Compounded semaglutide side effects are usually the familiar stomach symptoms caused by semaglutide itself. Compounding does not create a second, completely different side-effect list. What can change is the chance of a measurement mistake, a reaction to an added ingredient, the use of a different ingredient form, or a quality problem. That is why the vial's concentration, pharmacy label, and prescriber matter as much as the drug name.
Compounded semaglutide side effects start with the molecule
Semaglutide is a GLP-1 receptor agonist, a medicine that copies a gut hormone involved in fullness and blood sugar. Its effect on the digestive system explains why nausea and other stomach complaints can happen whether the product is a brand pen or a compounded prescription.
In STEP 1, a 2021 trial of 1,961 adults with overweight or obesity, nausea and diarrhea were the most common adverse events. About 1 in 22 participants receiving semaglutide stopped because of gastrointestinal symptoms: 4.5%, compared with 0.8% on placebo (Wilding and colleagues, New England Journal of Medicine). Those data describe the studied product and protocol. They do not prove that every compounded preparation has an identical safety profile.
The full symptom list, usual timing, and serious warning signs belong in the separate guide to semaglutide side effects. The useful question here is narrower: what can the compounding step add?
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
What the compounding step can add
A compounded medication is prepared by a pharmacy for an identified patient and prescription. The compounded semaglutide guide explains that framework in detail. For side effects, four practical differences matter.
| Possible issue | What changes | What it can look like |
|---|---|---|
| Concentration or unit error | The amount drawn from a vial may not match the prescribed amount | Symptoms that are much stronger than expected |
| Different ingredient form | Semaglutide sodium or acetate is not the ingredient used in approved products | An uncertain safety and drug-action profile |
| Added ingredient | Some preparations combine semaglutide with a vitamin or other compound | A reaction that semaglutide alone does not explain |
| Quality or sterility problem | The finished vial is not reviewed before marketing | Unexpected irritation, contamination, or unreliable potency |
This does not mean every compounded vial has one of these problems. It means the exact preparation matters, and brand-trial data cannot answer every question about it.
Dosing and unit errors can make ordinary effects severe
Milligrams describe an amount of medicine. Milliliters describe liquid volume. Syringe units are marks that measure volume, so the amount of semaglutide behind one unit changes when the vial's concentration changes.
That distinction has caused real harm. In a 2023 poison-center case series, three people became ill after administration errors involving compounded semaglutide. Two took ten times the intended amount. All three had nausea, vomiting, and abdominal pain, and one needed care with intravenous fluids (Lambson and colleagues, Journal of the American Pharmacists Association). Three cases cannot estimate how often this happens, but they show the mechanism clearly.
The FDA dosing-error alert describes reports of people receiving five to 20 times the intended amount. Some needed medical care or hospitalization. The agency tied the errors to varying concentrations, oversized syringes, and confusion among milligrams, milliliters, and units. The prescription, vial concentration, syringe, and pharmacy directions need to agree without a fresh calculation by the patient.
The same measurement problem can arise with other compounded GLP-1 medicines, including tirzepatide, even though tirzepatide is a different molecule with its own side-effect profile.
Salt forms and additives are separate questions
FDA's current GLP-1 concerns page says semaglutide sodium and semaglutide acetate are different active ingredients from the one used in approved semaglutide products. The agency says it does not have information showing those salts share the same chemical and drug-action properties, and it is unaware of a lawful basis for using them in compounding.
Added ingredients create a different question. FDA says some compounders add vitamin B12, vitamin B6, L-carnitine, or NAD, while the safety and effectiveness of those combinations have not been established. An ingredient's familiar name does not show that it prevents nausea or makes semaglutide work better. The prescription and dispensing label—not the telehealth company's name—identify what is actually in a particular preparation.
Sterility is about the finished vial and who stands behind it
Sterility means the absence of contaminating microbes. It matters especially for an injection because the needle crosses the body's protective skin barrier. FDA also notes that compounded drugs do not receive its premarket review for safety, effectiveness, or quality.
As of September 9, 2026, the day this article was written, an FDA warning letter dated August 24, 2026 described an online seller offering injectable semaglutide alongside a solution for mixing it and said the products were unapproved new drugs. The letter does not show that a patient-specific prescription from a licensed compounding pharmacy had the same problem. It shows why an anonymous vial and a pharmacy-dispensed medication are not the same path.
A pharmacy of record changes the practical safety picture. There is a named prescriber, a licensed U.S. pharmacy, a label tied to the exact concentration, a lot record connecting the vial to its batch, and a place to report a reaction. If a vial arrives warm, damaged, unexpectedly different, or unclearly labeled, that chain creates someone accountable for resolving it.
FDA's current page reports 990 adverse-event reports associated with compounded semaglutide as of May 31, 2026. That number is not an incidence rate, and an adverse-event report does not prove the product caused the event. FDA also notes that reporting by many state-licensed pharmacies is not mandatory, so the database is useful for signals, not a prediction for one patient.
When a reaction suggests more than routine nausea
Timing and intensity offer clues, though they cannot diagnose the cause. A familiar mild symptom around treatment initiation is different from repeated vomiting after a new vial or concentration. A spreading injection-site reaction, fever, cloudy liquid, damaged packaging, or a label that does not match the prescription raises a product-specific question rather than an ordinary semaglutide question.
Severe or persistent vomiting, an inability to keep fluids down, fainting, trouble breathing, or severe ongoing abdominal pain deserves urgent medical evaluation. For a suspected medication error or quality problem, the prescriber and dispensing pharmacy need the vial label, concentration, amount used, timing, and symptoms. That record is far more useful than trying another online unit conversion.
At Promise, a licensed provider reviews every request, and not everyone qualifies. If semaglutide is prescribed, follow-up stays connected to the clinical relationship so an unexpected reaction, label question, or concentration change has a clear place to go.